Head Office, Taiwan Blood Services Foundation, Taipei, Taiwan.
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Vox Sang. 2022 Jan;117(1):99-108. doi: 10.1111/vox.13133. Epub 2021 Jun 23.
Large-scale single nucleotide variation (SNV)-based blood group genotyping assays have been made available for over a decade. Due to differences in ethnic groups, there is much diversity in clinically important blood group antigens and genetic variants. Here, we developed a robust matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)-based blood group genotyping method on MassARRAY system.
A total of 1428 donors were enrolled into three groups: (a) reagent red cell donors; (b) rare donor or common antigen-negative donors; and (c) group O, R R /R R donors. Forty-two SNVs were designed for determining nine blood groups, with X/Y chromosome in two multiplex reactions, on MassARRAY 96-well format system. Further targeted sequence analyses were performed by Sanger sequencing.
WHO reference reagent (NIBSC code: 11/214) was tested for concordance with the provided genotype results. Among the donors, concordance rate was over 99%. Alleles of important phenotypes such as Mi(a+), Di(a+), and Asian-type DEL and alleles of rare blood groups such as Fy(a-), Jk(a-b-) and s- were screened. Three types of discrepancies were found. Serologically, the 'N' antigen was expressed on genetically MM with GYP*Mur red blood cells and caused genuine discrepancies (9.5%). Genetically, allele dropout (ADO) was caused by rare SNV in the primer for Ss genotype (2.1%) and partial insertion of RHD genes (0.9%) led to difficulties in predicting phenotypes.
Hemo panel module and MassARRAY System in 96-well format showed good performance in terms of large-scale blood group genotyping and phenotype predictions. Implementation of this method is effective for routine blood group genotype screening of donors.
大规模基于单核苷酸变异 (SNV) 的血型基因分型检测已经问世十多年。由于种族差异,临床上重要的血型抗原和遗传变异存在很大的多样性。在此,我们开发了一种基于基质辅助激光解吸/电离飞行时间 (MALDI-TOF) 的强大基因分型方法,该方法基于 MassARRAY 系统。
共有 1428 名供者被分为三组:(a) 试剂红细胞供者;(b) 稀有供者或常见抗原阴性供者;和 (c) O 组、RR /RR 供者。设计了 42 个 SNV 用于确定 9 个血型,两个多重反应在 MassARRAY 96 孔格式系统中包含 X/Y 染色体。进一步通过 Sanger 测序进行了靶向序列分析。
使用 WHO 参考试剂 (NIBSC 代码:11/214) 测试与提供的基因型结果的一致性。在供者中,一致性率超过 99%。筛选了重要表型如 Mi(a+)、Di(a+)和亚洲型 DEL 以及稀有血型如 Fy(a-)、Jk(a-b-)和 s- 的等位基因。发现了三种类型的差异。在血清学上,'N' 抗原在遗传上为 MM 并具有 GYP*Mur 红细胞上表达,导致真正的差异(9.5%)。遗传上,引物中罕见 SNV 导致等位基因缺失 (ADO)(2.1%),部分 RHD 基因插入导致表型预测困难(0.9%)。
Hemo 面板模块和 96 孔格式的 MassARRAY 系统在大规模血型基因分型和表型预测方面表现良好。该方法的实施对于供者常规血型基因筛查有效。